Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Idexx Laboratories (IDXX)

IDEXX raises 2025 revenue and EPS guidance after Q2 revenue rises 11% to $1,109 million

Positive Impact 4 of 5 guidance Written later

IDEXX Laboratories reported second-quarter 2025 revenue of $1,109 million, up 11% as reported and 9% organic, and diluted EPS of $3.63, up 49% as reported. The company raised its full-year 2025 revenue guidance to $4,205 million–$4,280 million and its EPS outlook to $12.40–$12.76, which shareholders will weigh against a prior-year litigation accrual that depressed the comparison base.

Key points

  • Q2 2025 revenue $1,109 million, up 11% as reported and 9% organic; comparable EPS $3.50, up 17%
  • Diluted EPS $3.63 included $0.07 from a discrete tax reserve release and $0.10 from share-based compensation tax benefits
  • 2025 revenue guidance raised to $4,205 million–$4,280 million, up $90 million at midpoint; EPS outlook raised by $0.40 at midpoint to $12.40–$12.76
  • Investor Day scheduled for August 14, 2025

The filing

CompanyIdexx Laboratories (IDXX)
Form8-K, current report
Filed with the SECAug 4, 2025, 6:30 AM ET
Accession number0001104659-25-073304

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.